The diagnosis of inflammatory bowel disease (IBD) remains a challenge for clinicians, and patients. Clinical suspicion of these disorders leads to a diagnostic pathway that may include stool testing, colonoscopy, radiological tests and capsule examinations. This workup is unpleasant, embarrassing, painful and occasionally dangerous. Alternative means of diagnosing IBD are being explored. Genetic testing and serology have not been found to be sufficiently specific or sensitive to be used for diagnosis. Faecal markers, however, have demonstrated some potential. Faecal lactoferrin and calprotectin may be used to differentiate IBD from non-inflammatory disorders and these tests are now commonly used, with support from the National Institute for Health and Care Excellence. Recent research has focused upon volatile organic compounds emitted from bodily fluids, including faeces, urine and breath. Headspace gas from faeces or urine may be analysed by gas chromatography/mass spectrometry. Models have been built based on these compounds to enable Crohn's disease and ulcerative colitis to be distinguished from irritable bowel syndrome (IBS) and from healthy controls. Similar work has found that headspace gases from urine may be used to diagnose IBS. Faecal samples are relatively easy to obtain, but patients dislike collecting samples, so a urinary test is an attractive alternative. Early data from breath samples also show potential and will be presented. Non-invasive diagnosis of IBD is becoming a reality that will save patients from discomfort, embarrassment and risk, and may mean significant savings for healthcare providers.

Keywords:
Biomarkers, Calprotectin, Volatile organic compounds
1.
Sidler MA, Leach ST, Day AS: Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008;14:359-366.
2.
Dubinsky MC, Kugathasan S, Mei L, et al: Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105-1111.
3.
Lichtenstein GR, Targan SR, Dubinsky MC, et al: Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010;17:2488-2496.
4.
Schoepfer AM, Trummler M, Seeholzer P, et al: Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-39.
5.
van Rheenen PF, Van de Vijver E, Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341: c3369.
6.
Schoepfer AM, Beglinger C, Straumann A, et al: Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-1858.
7.
Schoepfer AM, Beglinger C, Straumann A, et al: Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-169.
8.
Stein SE: An integrated method for spectrum extraction and compound identification from gas chromatography/mass spectrometry data. J Am Soc Mass Spectrom 1999;10:770-781.
9.
Aggio R, Villas-Boas SG, Ruggiero K: Metab: an R package for high-throughput analysis of metabolomics data generated by GC-MS. Bioinformatics 2011;27:2316-2318.
10.
Xia J, Wishart DS: Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 2011;6:743-760.
11.
Smith CA, Want EJ, O'Maille G, et al: XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 2006;78:779-787.
12.
Garner CE, Smith S, de Lacy Costello B, et al: Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J 2007;21:1675-1688.
13.
Garner CE, Smith S, Bardhan PK, et al: A pilot study of faecal volatile organic compounds in faeces from cholera patients in Bangladesh to determine their utility in disease diagnosis. Trans R Soc Trop Med Hyg 2009;103:1171-1173.
14.
Garner CE, Ewer A, Elasouad K, et al: Analysis of faecal volatile organic compounds in preterm infants who develop necrotising enterocolitis: a pilot study. J Pediatr Gastroenterol Nutr 2009;49:559-565.
15.
Ahmed I, Greenwood R, Costello BDL, et al: An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS One 2013;8:e58204.
16.
Walton C, Fowler DP, Turner C, et al: Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm Bowel Dis 2013;19:2069-2078.
17.
Jayasena H, Khalid T, Probert CS: Diagnostic potential of volatile organic compounds as urine biomarkers in inflammatory bowel disease. Gut 2013;62(suppl 1):A76-A77.
18.
Bodelier AGH, Smolinska A, Dallinga JW, et al: Volatile organic compounds in breath as new test for Crohn's disease activity. United European Gastroenterologica Week Online Programme 117-LB5.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.